Quarterly report · Q2
4886.TEDINET S100PIUD
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥28.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥4.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥86.2bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥78.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.2bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥52.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.2bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥199m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥427m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥83.18 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-98.52 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-137.17 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥114m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥86m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥20m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥473m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥231m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥93m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥66m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥26m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥342m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥229m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥25.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥25.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥26m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 470
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | CurrentQuarterInstant | 17224000000 | JPY |
| Salaries allowances and bonuses sga | Prior1YTDDuration | 1666000000 | JPY |
| Salaries allowances and bonuses sga | CurrentYTDDuration | 1676000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 760000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 781000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 241000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 226000000 | JPY |
| Transportation warehousing expenses sga | Prior1YTDDuration | 2899000000 | JPY |
| Transportation warehousing expenses sga | CurrentYTDDuration | 3051000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 1941000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 1768000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 25619000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 2791000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 66000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 28477000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 28477000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 26000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 26000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -26000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 25619000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 2791000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 93000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 28504000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -26000000 | JPY |
| Net sales | Prior1YTDDuration | 28477000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 2797000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 229000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -26000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3000000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -342000000 | JPY |
| Operating income | Prior1YTDDuration | 2657000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 26851000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 3234000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 86000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 30172000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 30172000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 28000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -28000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 26851000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 3234000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 114000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |